Abstract
The moonlighting protein, Prdx-6, exhibits peroxidase activity, phospholipase activity, and lysophosphatidylcholine acyltransferase (LPCAT) activity. Although it is ubiquitous in expression, its level is prominently high in the lung. Prdx-6 has been known to be an important enzyme for the maintenance of normal lung physiologies including, anti-oxidant defense, lung surfactant homeostasis, and cell signaling. Studies further unveiled that the altered activity (peroxidase or ai- PLA2) of this enzyme is linked with various lung pathologies or diseases. In the present article, we attempted to address the various pathophysiologies or disease conditions (like lung ischemia, hyperoxia, lung cancer, emphysema, and acute lung injury) wherein Prdx-6 is involved. The study implicates that Prdx-6 could be used as a common drug target for multiple lung diseases. Important future insights have also been incorporated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
